Our Pricing

Wegovy Timeline: All 5 Doses From Start to Success

Understanding the wegovy timeline UK dose schedule is essential for setting realistic expectations during your weight loss journey. Wegovy follows a carefully structured five-stage escalation protocol over 16 weeks, gradually increasing from 0.25mg to the maintenance dose of 2.4mg weekly. This gradual approach, validated in the STEP clinical trial programme, minimises gastrointestinal side effects while optimising weight loss outcomes [1].

The Five-Stage Wegovy Dose Escalation Timeline

Wegovy's dose escalation follows a precise 16-week schedule designed by Novo Nordisk and approved by the MHRA. Each stage lasts four weeks, allowing your body to adapt to increasing semaglutide levels before progressing to the next dose [1].

The five doses are: 0.25mg (weeks 1-4), 0.5mg (weeks 5-8), 1mg (weeks 9-12), 1.7mg (weeks 13-16), and 2.4mg (week 17 onwards as your maintenance dose). This gradual titration significantly reduces the risk of nausea and vomiting compared to starting at higher doses [2].

At Cured Pharmacy, we supply genuine UK-licensed Wegovy pens at £79.00, with each pen containing four pre-filled doses. Your UK prescriber will determine your starting point based on your clinical assessment, and you'll progress through the schedule under ongoing medical supervision.

What to Expect During Weeks 1-4: The 0.25mg Starting Dose

The initial 0.25mg dose serves as an introduction phase. Most patients experience minimal side effects at this stage, though some report mild nausea or reduced appetite within 24-48 hours of the first injection [2].

Weight loss during month one is typically modest — clinical trial data shows an average of 1-2% body weight reduction during this phase. The primary goal is physiological adaptation rather than dramatic weight loss. Your body is beginning to respond to semaglutide's effects on GLP-1 receptors in the brain and digestive system [1].

This is when you'll establish your injection routine. Wegovy can be administered any day of the week, at any time, with or without food. Consistency matters more than timing — choose a day you'll remember and stick to it throughout your treatment journey.

Managing Early Side Effects

If you experience nausea during the first month, eat smaller meals more frequently and avoid high-fat foods. Stay well-hydrated and consider taking your injection in the evening so any queasiness occurs during sleep. These symptoms typically diminish as your body adjusts to the medication [2].

Weeks 5-12: Building Momentum With 0.5mg and 1mg Doses

The second and third dose stages represent the acceleration phase of your wegovy timeline UK dose schedule. At 0.5mg (weeks 5-8), most patients notice a significant reduction in appetite and food cravings. This is when weight loss becomes more noticeable, with average reductions of 3-5% body weight by week 12 [1].

When you progress to 1mg at week 9, the medication's full appetite-suppressing effects become evident. The STEP-1 trial documented that by week 12, participants had lost an average of 6% of their starting body weight — a clinically significant threshold associated with improved metabolic markers [1][3].

Side effects may intensify temporarily when stepping up to each new dose, particularly gastrointestinal symptoms like nausea, constipation, or diarrhoea. These typically resolve within 3-5 days as your body adjusts. If symptoms persist or become severe, your UK prescriber may recommend staying at your current dose for an additional four weeks before progressing.

Dietary Adjustments for Optimal Results

During this phase, focus on protein-rich foods to preserve muscle mass while losing fat. Aim for 1.2-1.6g of protein per kilogram of body weight daily. Combine Wegovy with a balanced diet and regular physical activity — clinical trials showed significantly better outcomes when medication was paired with lifestyle interventions [3].

Weeks 13-20: Reaching Maintenance With 1.7mg and 2.4mg

The 1.7mg dose (weeks 13-16) serves as a bridge to your maintenance dose. By this stage, most patients have established new eating patterns and report feeling satisfied with smaller portions. Average weight loss by week 16 typically reaches 8-10% of starting body weight [1].

At week 17, you reach the 2.4mg maintenance dose — the therapeutic target validated across the STEP trial programme. This is the dose you'll continue long-term to sustain weight loss. In the landmark STEP-1 trial, participants on 2.4mg semaglutide achieved an average 14.9% body weight reduction over 68 weeks, compared to 2.4% with placebo [1][3].

Weight loss continues throughout the first year on maintenance dosing, though the rate typically slows after six months. Peak weight loss usually occurs between weeks 60-68, after which weight stabilises if you maintain treatment and lifestyle modifications [3].

Long-Term Treatment Considerations

Wegovy is designed for chronic weight management, not short-term use. The STEP-4 trial demonstrated that patients who discontinued semaglutide after 20 weeks regained two-thirds of their lost weight within one year, whilst those who continued treatment maintained their weight loss [4]. Your UK prescriber will conduct regular reviews to assess ongoing suitability and adjust your treatment plan as needed.

When Will You See Results? Timeline for Weight Loss

Most patients notice initial weight loss within 4-8 weeks of starting Wegovy, though individual responses vary considerably. Clinical trial data shows the following average timeline: 2-3% weight loss by week 4, 5-7% by week 12, 10-12% by week 28, and 14-15% by week 68 [1][3].

Factors influencing your personal timeline include starting BMI, adherence to dietary changes, physical activity levels, metabolic health, and genetic factors affecting GLP-1 receptor sensitivity. Patients with higher starting BMIs often see more absolute weight loss, whilst those with lower BMIs may see slower but still clinically meaningful reductions [3].

It's important to set realistic expectations. Wegovy is not a rapid weight loss solution — it works gradually by reducing appetite and caloric intake over many months. The MHRA-approved indication requires achieving at least 5% weight loss within the first 12-16 weeks to justify continued treatment, though most patients exceed this threshold [1].

Comparing Wegovy Timeline to Other Weight Loss Treatments

Understanding how Wegovy's timeline compares to alternatives helps set appropriate expectations. Saxenda (liraglutide) requires daily injections and typically produces 5-8% weight loss over one year — less than Wegovy's average outcomes [5]. Orlistat, an oral medication, produces modest 3-5% weight loss but works through fat malabsorption rather than appetite suppression.

Mounjaro (tirzepatide), a dual GIP/GLP-1 receptor agonist, follows a similar dose escalation timeline but achieves greater average weight loss — up to 22.5% in clinical trials over 72 weeks [6]. However, it currently costs more than Wegovy and may not be suitable for all patients.

Your UK prescriber will recommend the most appropriate treatment based on your medical history, weight loss goals, budget, and tolerance for side effects. All prescription weight loss medications available through Cured Pharmacy require clinical assessment and ongoing monitoring to ensure safety and efficacy.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Novo Nordisk. (2023). Wegovy (semaglutide) Summary of Product Characteristics. Medicines and Healthcare products Regulatory Agency. Retrieved from https://www.medicines.org.uk/emc/product/13799
3. Garvey, W. T., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4
4. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224
5. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
6. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine and individual results may vary. Weight loss outcomes depend on adherence to treatment, dietary modifications, and lifestyle factors.